Glooko Appoints Former Eli Lilly & Company Senior Executive Alfonso “Chito” Zulueta to Board of Directors
PALO ALTO, Calif., April 28, 2022 /PRNewswire/ — Glooko, Inc., a leading provider of remote patient monitoring and data management solutions for diabetes and related chronic conditions, today announced the appointment of Alfonso “Chito Zulueta to its board of directors.
Respected as a leader with a solid track record of success in the pharmaceutical industry and extensive board and industry association experience, Mr. Zulueta joins Glooko’s Board of Directors after serving as senior executive position leading a wide range of global business and business units over his more than 30-year career with Eli Lilly and Company. Glooko’s management team and Board of Directors welcome the breadth and depth of experience he brings as the company continues its strategic growth as a digital health leader in the chronic disease management.
“We are very excited to have Chito join our Board of Directors and particularly fortunate for his strong understanding of the impact digital health solutions can have on chronic disease management,” said Russ Johannesson, CEO of Glooko. “He brings a wealth of valuable experience and unique perspectives to our Board, having successfully led global healthcare businesses focused on treating diabetes and other diseases. Chito’s appointment comes at a critical time. for Glooko, as we continue to expand our digital therapy (DTx) and clinical research businesses.”
Mr. Zulueta retired at the end of 2021 from his role at Lilly as a member of the executive committee, leader and president of the company’s international business unit, where he was responsible for leading Lilly’s activities in all areas. geographies outside of the United States and Canada. Previously, he was President of Lilly’s Emerging Markets Division, President of JapanPresident of the Global Oncology and Critical Care Products Group, Vice President of US Sales and Marketing for the Neurosciences and Diabetes/Family Health Business Unit, and Vice President of Global Marketing.
“It’s an irresistible time to join Glooko’s board of directors as the company expands its offerings and business footprint,” Mr. Zulueta said. “Glooko is rapidly increasing its market relevance and driving true innovation through its digital health solutions, serving more patients and healthcare professionals worldwide. I am delighted to use my experience and knowledge to help Glooko accelerate this growth and evolution. »
Mr. Zulueta also serves on the boards of CTS Corporate, Syneos Health and Calidi Biotherapeutics, Inc. He has previously served on the boards of industry associations, including the European Federation of Pharmaceutical Industries and Associations (Chairman of the International Committee ), PhRMA (Chairman of the Japan corporate executive committee), the American Chamber of Commerce of Japan (governor of the Kansai chapter), and the US-Japan Business Council.
Mr. Zulueta holds an MBA from the Darden School of Business Administration in University of Virginia and a bachelor’s degree in economics from De La Salle University.
Glooko is transforming digital health by connecting people living with diabetes and related chronic conditions with their healthcare teams, enabling collaborative telehealth, clinical research and improving health outcomes. The company’s software platforms collect and analyze data from multiple devices in one highly secure location, enabling easy remote download via app or in-clinic, and producing easy-to-read analytics through actionable charts and graphs . The platform is compatible with more than 95% of global diabetes and health monitoring devices, giving patients and their providers flexibility in managing their conditions. With over 35 billion data points, Glooko is the world leader in diabetes patient data. Glooko’s solutions can be found in 31 countries in 22 languages. Learn more about glooko.com.
Director of Global Communications, Glooko